GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (BSP:ABBV34) » Definitions » Cyclically Adjusted Price-to-FCF

AbbVie (BSP:ABBV34) Cyclically Adjusted Price-to-FCF : 17.68 (As of May. 17, 2024)


View and export this data going back to 2016. Start your Free Trial

What is AbbVie Cyclically Adjusted Price-to-FCF?

As of today (2024-05-17), AbbVie's current share price is R$52.50. AbbVie's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was R$2.97. AbbVie's Cyclically Adjusted Price-to-FCF for today is 17.68.

The historical rank and industry rank for AbbVie's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BSP:ABBV34' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 15.05   Med: 18.39   Max: 23.97
Current: 17.24

During the past years, AbbVie's highest Cyclically Adjusted Price-to-FCF was 23.97. The lowest was 15.05. And the median was 18.39.

BSP:ABBV34's Cyclically Adjusted Price-to-FCF is ranked better than
75.84% of 327 companies
in the Drug Manufacturers industry
Industry Median: 33.44 vs BSP:ABBV34: 17.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AbbVie's adjusted free cash flow per share data for the three months ended in Mar. 2024 was R$0.675. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is R$2.97 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AbbVie Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AbbVie's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Cyclically Adjusted Price-to-FCF Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 18.76 19.53 19.55 16.63

AbbVie Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.65 15.26 16.23 16.63 19.17

Competitive Comparison of AbbVie's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted Price-to-FCF falls into.



AbbVie Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AbbVie's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=52.50/2.97
=17.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AbbVie's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.675/131.7762*131.7762
=0.675

Current CPI (Mar. 2024) = 131.7762.

AbbVie Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.137 100.560 0.180
201409 0.146 100.428 0.192
201412 -0.075 99.070 -0.100
201503 0.176 99.621 0.233
201506 0.204 100.684 0.267
201509 0.297 100.392 0.390
201512 0.268 99.792 0.354
201603 0.285 100.470 0.374
201606 0.234 101.688 0.303
201609 0.166 101.861 0.215
201612 0.184 101.863 0.238
201703 0.245 102.862 0.314
201706 0.242 103.349 0.309
201709 0.384 104.136 0.486
201712 0.308 104.011 0.390
201803 0.324 105.290 0.406
201806 0.413 106.317 0.512
201809 0.719 106.507 0.890
201812 0.529 105.998 0.658
201903 0.471 107.251 0.579
201906 0.381 108.070 0.465
201909 0.764 108.329 0.929
201912 0.537 108.420 0.653
202003 0.759 108.902 0.918
202006 0.573 108.767 0.694
202009 1.068 109.815 1.282
202012 0.826 109.897 0.990
202103 0.930 111.754 1.097
202106 0.831 114.631 0.955
202109 1.433 115.734 1.632
202112 0.971 117.630 1.088
202203 0.830 121.301 0.902
202206 0.864 125.017 0.911
202209 1.370 125.227 1.442
202212 1.328 125.222 1.398
202303 0.736 127.348 0.762
202306 1.052 128.729 1.077
202309 1.282 129.860 1.301
202312 0.784 129.419 0.798
202403 0.675 131.776 0.675

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AbbVie  (BSP:ABBV34) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AbbVie Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AbbVie's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie (BSP:ABBV34) Business Description

Industry
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

AbbVie (BSP:ABBV34) Headlines

No Headlines